<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624684</url>
  </required_header>
  <id_info>
    <org_study_id>MORICUP-PCR study</org_study_id>
    <nct_id>NCT05624684</nct_id>
  </id_info>
  <brief_title>Diagnostic Performance and Impact of a Multiplex PCR Pneumonia Panel in ICU Patients With Severe Pneumonia.</brief_title>
  <official_title>Diagnostic Performance and Impact of a Multiplex PCR Pneumonia Panel on the Early Adaptation of Antimicrobial Therapy in ICU Patients With Severe Pneumonia. A Prospective Multicentric Observational Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avicenna Military Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avicenna Military Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the diagnostic performance of multiplex respiratory&#xD;
      PCR (PCR-RM) compared to standard microbiological tests and its potential impact on the early&#xD;
      adaptation of antibiotic treatment in intensive care patients with severe pneumonia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, observational, multicenter ICU study. Adult patients with severe&#xD;
      pneumonia requiring invasive mechanical ventilation will be included. Severe pneumonia&#xD;
      consists of 3 categories of pneumonia: community-acquired pneumonia (CAP), hospital-acquired&#xD;
      pneumonia (HAP), and ventilator-acquired pneumonia (VAP). The microbiological testing will be&#xD;
      performed before antibiotic initiation on tracheobronchial aspirations, protected distal&#xD;
      sampling, or mini-bronchoalveolar lavage as part of routine care. No additional samples will&#xD;
      becollected for this study. Respiratory samples will be simultaneously tested by conventional&#xD;
      microbiological techniques and multiplex respiratory PCR [PCR-RM] (BIOFIRE® FILMARRAY®&#xD;
      Pneumonia Panel Plus). Classical microbiological culture (CMC) will be considered the gold&#xD;
      standard for microbiological pneumonia diagnosis. The agreement between the results of the&#xD;
      Pneumonia Plus® panel and the results of conventional microbial culture (CMC) will be&#xD;
      assessed.&#xD;
&#xD;
      An empiric antibiotic therapy will be prescribed according to the local ecology and the&#xD;
      protocols of each ICU unit. Two senior experts in each participating center will have to&#xD;
      approve the antibiotic prescription. The antibiotic therapy could be modified after the&#xD;
      reception of the Mutilpex PCR results by the two senior experts. After the reception of the&#xD;
      results of the classic microbiological culture, the previous antibiotic changes will be&#xD;
      judged as appropriate or inappropriate by a multidisciplinary team including intensivists,&#xD;
      infectious disease specialists, and microbiologists. Appropriate changes include adequacy,&#xD;
      de-escalation, and optimization of antibiotic therapy, and inappropriate changes include&#xD;
      inadequacy, escalation, and de-optimization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2023</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of diagnostic concordance between Classical microbiological cultures and the respiratory multiplex PCR (RM-PCR) and conventional microbiological cultures (CMC) to identify pathogens responsible for severe pneumonia in critically ill patients.</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Classical microbiological cultures (CMC) will serve as the gold standard for the comparison between techniques, considering a test result:&#xD;
A true positive, when CMC and RM-PCR have identified the same microorganism (CMC+, PCR-RM +).&#xD;
A false positive, when RM-PCR detected an organism but not CMC (CMC-, RM-PCR+)&#xD;
A true negative, when no method detected any microorganism (CMC-, RM-PCR -)&#xD;
A false negative, when CMC but not RM-PCR has detected an organism (CMC+, RM-PCR -).&#xD;
Sensitivity, specificity, and positive and negative predictive values for the respiratory multiplex PCR will be calculated using the precedent findings.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The impact of the respiratory multiplex PCR (RM-PCR) on the appropriateness of empirical antimicrobial therapy.</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>The proportion of patients for whom the respiratory multiplex PCR (RM-PCR) induces an appropriate change of antibiotic therapy. Appropriate changes include adequacy, de-escalation, and escalation of antibiotic treatment.&#xD;
Adequacy is defined as introducing an antibiotic to cover a microorganism that was not adequately treated before the results of RM-PCR.&#xD;
Escalation is defined by a widening of the ATB spectrum to cover a pathogen not taken into account or the detection of resistance genes.&#xD;
De-escalation is defined as the use of a narrower-spectrum anti-infective or the discontinuation of an ATB combination.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Community-acquired Pneumonia</condition>
  <condition>Hospital-acquired Pneumonia</condition>
  <condition>Ventilator Associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>ICU patients with severe pneumonia</arm_group_label>
    <description>Critically ill patients with severe pneumonia under mechanical ventilation including ventilator-associated pneumonia, community-acquired or hospital-acquired pneumonia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Multiplex respiratory PCR</intervention_name>
    <description>The BIOFIRE® FILMARRAY® Pneumonia plus Panel</description>
    <arm_group_label>ICU patients with severe pneumonia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients with ventilator-associated pneumonia (VAP), community-acquired&#xD;
        pneumonia (CAP), or hospital-acquired pneumonia (HAP). For CAP and HAP, only patients under&#xD;
        invasive mechanical ventilation will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  critically ill adult patients&#xD;
&#xD;
          -  clinical, biological, and radiological signs of severe pneumonia.&#xD;
&#xD;
          -  community-acquired pneumonia, hospital-acquired pneumonia, or ventilator-associated&#xD;
             pneumonia&#xD;
&#xD;
          -  invasive mechanical ventilation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Non-invasive mechanical ventilation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Younes Aissaoui, MD</last_name>
    <phone>+212661403332</phone>
    <email>younes.aissaoui@live.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ayoub Belhadl, MD</last_name>
    <phone>+212670279562</phone>
    <email>ayoubbelhadj@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Avicenna Military Hospital</name>
      <address>
        <city>Marrakesh</city>
        <state>Marrakesh Tensift El Haouz</state>
        <zip>40000</zip>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Younes Aissaoui, MD</last_name>
      <phone>+21266140333</phone>
      <email>younes.aissaoui@live.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>Morocco</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>November 4, 2022</study_first_submitted>
  <study_first_submitted_qc>November 18, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>February 3, 2023</last_update_submitted>
  <last_update_submitted_qc>February 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Avicenna Military Hospital</investigator_affiliation>
    <investigator_full_name>Younes Aissaoui, MD</investigator_full_name>
    <investigator_title>Professor of Anesthesiology and Intensive Care Medicine - Head of surgical intensive care unit</investigator_title>
  </responsible_party>
  <keyword>Community-acquired Pneumonia</keyword>
  <keyword>Hospital-acquired Pneumonia</keyword>
  <keyword>Ventilator Associated Pneumonia</keyword>
  <keyword>Multiplex PCR</keyword>
  <keyword>Antibiotic stewardship</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Healthcare-Associated Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The datasets of the study will be available from the principal investigator on reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>until 5 years after study completion</ipd_time_frame>
    <ipd_access_criteria>Healthcare workers.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

